Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease progression with the targeted agent afatinib (Gilotrif) versus chemotherapy, a ...

According to the findings, there is an indication of a major added benefit in patients with the EGFR mutation Del19, and a hint of a minor added benefit of afatinib in patients under the age of 65 ...

1 Importantly, patients taking afatinib* with the most common EGFR mutations (del19 and L858R, accounting for 90% of all EGFR mutations) lived for well over a year without progression (PFS of 13.6 ...

The study assessed the impact of first-line treatment with Gilotrif ® (afatinib) followed by osimertinib in Del19/L858R epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell ...

The improvement in PFS with afatinib was consistent across most pre-defined subgroups, including gender, age, race, and EGFR mutation type. Data regarding OS, the study’s third co-primary ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of afatinib, having considered evidence on the nature of epidermal growth factor receptor (EGFR) ...

“Not only did LUX-Lung 3 meet its primary endpoint, but it also showed that afatinib*, especially in patients with the most common EGFR mutations, almost doubled the progression free survival ...